Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02051790 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Reader Training Processes

A Phase 4 study, sponsored by Avid Radiopharmaceuticals.

Completed
Registry status
Phase 4
Development phase
241
Enrollment target

NCT02051790 is a Phase 4 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 241 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02051790, a Phase 4 study, has completed, sponsored by Avid Radiopharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
241 participants
Enrollment target

Study Summary

This study is designed to evaluate the agreement between florbetapir F 18 scan interpretation in the clinic and by expert readers.

Interventions

  • DRUG florbetapir F 18

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2014-03
Est. Completion 2014-08
Phase Phase 4

Sponsor

Avid Radiopharmaceuticals

42 total trials

What the Registry Record Tells You About NCT02051790

The ClinicalTrials.gov registry entry for NCT02051790 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.

NCT02051790 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02051790 about?

NCT02051790 is a clinical study titled "Evaluation of Reader Training Processes". This study is designed to evaluate the agreement between florbetapir F 18 scan interpretation in the clinic and by expert readers.

What is the current status of trial NCT02051790?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 241 participants. The study started on 2014-03. Estimated completion is 2014-08.

What interventions are being tested in trial NCT02051790?

The interventions under investigation include: florbetapir F 18 (DRUG).

Who is sponsoring clinical trial NCT02051790?

This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.